Inflammatory pain mediators

Inflammatory pain mediators, often collectively referred to as the "inflammatory soup," are a diverse group of biochemical substances released from damaged tissues, immune cells, and nerve endings during injury or infection [1.3.1, 1.3.3]. This group includes eicosanoids like prostaglandins, cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1β, IL-6), neuropeptides like substance P and calcitonin gene-related peptide (CGRP), and growth factors such as nerve growth factor (NGF) [1.3.2, 1.3.4]. These mediators function by binding to specific receptors on nociceptors, leading to peripheral sensitization and an increased sensitivity to painful stimuli (hyperalgesia) [1.3.1, 1.3.2]. In chronic conditions like osteoarthritis and rheumatoid arthritis, the persistent release of these mediators drives ongoing pain and contributes to tissue degradation [1.2.3, 1.3.1]. Therapeutic interventions target these mediators through various mechanisms, including the inhibition of their synthesis (e.g., NSAIDs for prostaglandins) or the direct neutralization of the ligands using monoclonal antibodies (e.g., anti-TNF or anti-NGF therapies) [1.1.2, 1.3.4]. Novel approaches, such as "pain sponge" technologies using iPSC-derived neurons, are also being developed to sequester these mediators locally within joints to provide relief without systemic side effects [1.2.2]. While effective, these treatments can be associated with significant safety concerns, such as gastrointestinal toxicity, cardiovascular risks, and impaired immune function [1.2.2, 1.3.4].

Other names

Inflammatory soupAlgesic mediatorsPro-nociceptive mediatorsInflammatory factorsAlgesic molecules

Inhibition of cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis; neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1beta) or growth factors (e.g., NGF) using monoclonal antibodies; antagonism of specific mediator receptors such as CGRP or bradykinin receptors [1.1.2, 1.3.1, 1.3.4].